AVALIAÇÃO CONTEXTUAL DO POTENCIAL DE APLICABILIDADE TERAPÊUTICA DOS FÁRMACOS DERIVADOS DO CANABIDIOL NO TRATAMENTO DA DOENÇA DE ALZHEIMER

Abstract

Objective: To carry out a correlational analysis between the symptoms present in Alzheimer's disease and its attenuation with the use of cannabinoid-based therapy. Bibliographic review: Alzheimer's disease is characterized by the progressive impairment of the individual's neurocognitive functions, ranging from recent memory loss - in the initial phase of the disease - to the impairment of most cognition and motor capacity - in more advanced pathological stages -, requiring the implementation of therapeutic approaches capable of slowing down the symptoms of the disease and limiting its rate of progression. Nowadays, as an alternative to the drugs mostly used in the treatment of Alzheimer's disease, the feasibility of therapies based on the use of cannabinoids has been verified, so that the mechanisms of action, therapeutic potentials and risks associated with the administration of such a drug class have been increasingly unraveled. Final considerations: Through the increasing analytical detail about the characteristics of cannabinoids - and the so-called endocannabinoid system -, the feasibility of their use in the treatment of pathologies such as Alzheimer's disease is increasingly substantiated, considering, continuously, the pathophysiological benefits and the limitations inherent to such therapy, in order to provide the affected patients with a viable and effective treatment.